液体活检标志物在非小细胞肺癌中的临床应用和挑战

Clinical application and challenges of liquid biopsy biomarkers in non-small cell lung cancer

肺癌是我国发病率和死亡率最高的恶性肿瘤。液体活检具有快捷、无创、可重复等传统组织活检不具备的优点,在非小细胞肺癌(NSCLC)的精准诊疗决策中具有重要的价值。文章简述液体活检在肺癌筛查、早期诊断、疗效和预后评估,以及耐药监测等方面的应用。并对液体活检技术面临的挑战:需进一步提高检测的敏感性和特异性,建立标准化的流程和参考区间,增加前瞻性临床研究验证,推动其实现临床转化,进行简评。

Lung cancer is a malignant tumor with the highest incidence and mortality in China.Liquid biopsy offers advantages such as speed,non-invasiveness and repeatability over traditional tissue biopsy,making it of value in precision medicine and treatment decision for non-small cell lung cancer(NSCLC).This review provides a brief overview of liquid biopsy in screening,early diagnosis,treatment and prognosis evaluation and resistance surveillance.In the future,new technology of liquid biopsy needs to be further improved for sensitivity and specificity,and standardized processes and reference intervals need to be established.Prospective clinical trials also need to be conducted before its clinical transformation.